cell line: NSCLC cell line HCC827
treatment: ClonTracer-barcoded HCC827 cell population was treated with 0.1% DMSO for 4 days.
resistant to: Vehicle control - Treated with 0.1% DMSO
cell line: NSCLC cell line HCC827
treatment: ClonTracer-barcoded HCC827 cell population was treated with 0.1% DMSO for 4 days.
resistant to: Vehicle control - Treated with 0.1% DMSO
cell line: NSCLC cell line HCC827
treatment: ClonTracer-barcoded HCC827 cell population was treated with 2 µM erlotinib for 47 days to generate the erlotinib-resistant cell population.
resistant to: 2 µM erlotinib
cell line: NSCLC cell line HCC827
treatment: ClonTracer-barcoded HCC827 cell population was treated with 2 µM erlotinib for 47 days to generate the erlotinib-resistant cell population.
resistant to: 2 µM erlotinib
cell line: NSCLC cell line HCC827
treatment: The erlotinib-resistant HCC827 cell population was treated with 2 µM erlotinib+0.2 µM crizotinib combination for 10 days to enrich for erlotinib/crizotinib dual-resistant subpopulations.
resistant to: 2 µM erlotinib+0.2 µM crizotinib combination
cell line: NSCLC cell line HCC827
treatment: The erlotinib-resistant HCC827 cell population was treated with 2 µM erlotinib+0.2 µM crizotinib combination for 10 days to enrich for erlotinib/crizotinib dual-resistant subpopulations.
resistant to: 2 µM erlotinib+0.2 µM crizotinib combination